



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	337666	Metibol Xcell
ARTG entry for	Medicine Listed	
Sponsor	Bio Concepts Pty Ltd	
Postal Address	PO Box 190, Banyo, Brisbane, QLD, 4014 Australia	
ARTG Start Date	10/06/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Metibol Xcell

Product Type	Single Medicine Product	Effective Date	10/06/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support energy production
Maintain/support healthy eye function
Maintain/support eye health
Maintain/support general health and wellbeing
Helps maintain/support healthy blood sugar/glucose
Maintain/support cardiovascular system health
Aid/assist/helps glucose/sugar/carbohydrate metabolism
Maintain/support (state vitamin/mineral/nutrient) levels in the body
Helps maintain/support cellular uptake of (state vitamin/mineral/nutrient)
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)

Indication Requirements

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Product presentation must not imply or refer to serious cardiovascular conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.



Australian Government
Department of Health
Therapeutic Goods Administration

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

alpha lipoic acid	300 mg
Biotin	1 mg
chromic chloride hexahydrate	1.35 mg
Equivalent: chromium	250 microgram
chromium picolinate	400 microgram
Equivalent: chromium	50 microgram
Cinnamomum cassia stem bark Extract dry concentrate	75 mg
Equivalent: Cinnamomum cassia (Dry)	1.5 g
Gymnema sylvestre leaf Extract dry concentrate standardised	70 mg
Equivalent: Gymnema sylvestre (Dry)	1.4 g
Nigella sativa seed Extract dry concentrate	37.5 mg
Equivalent: Nigella sativa (Dry)	750 mg

Other Ingredients (Excipients)

colloidal anhydrous silica

disodium edetate

gellan gum

hypromellose

magnesium stearate

microcrystalline cellulose

potable water

potassium acetate

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.